The company,Trovagene, based in San Diego, Calif., announced in mid-January that it has entered into contracts to distribute its Trovera tests with a number of partners in Europe and the Middle East. Including Bulgaria, where the contract partner is NM Genomix.
Advanced non-small cell lung cancer is a major goal for the development of target therapies. At the moment, several therapies have been approved or are in the clinical trials stage. The assessment of their potential benefits is based on the mutation status of genes such as EGFR, ALK, ROS1 and others.